Provided by Tiger Trade Technology Pte. Ltd.

Lipocine

7.15
-0.2500-3.38%
Post-market: 7.150.00000.00%16:25 EDT
Volume:65.02K
Turnover:467.05K
Market Cap:52.19M
PE:-4.05
High:7.66
Open:7.40
Low:6.89
Close:7.40
52wk High:12.37
52wk Low:2.52
Shares:7.30M
Float Shares:6.61M
Volume Ratio:0.77
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7669
EPS(LYR):-1.7669
ROE:-54.28%
ROA:-32.81%
PB:3.61
PE(LYR):-4.05

Loading ...

Lipocine Inc: on Track to Report Topline Results Early in Q2 of 2026

THOMSON REUTERS
·
Jan 12

Lipocine Inc - Dsmb Recommends Trial Continue Without Modification

THOMSON REUTERS
·
Jan 12

Lipocine Nears Full Enrollment in Phase 3 Trial of Oral Brexanolone for Postpartum Depression

Reuters
·
Dec 16, 2025

Lipocine Director Jeffrey Fink Resigns Effective January 1

Reuters
·
Dec 16, 2025

Lipocine Q3 EPS USD -0.59

Reuters
·
Nov 20, 2025

Lipocine Updates Corporate Presentation for Investors

TIPRANKS
·
Nov 18, 2025

Lipocine Reports Positive Interim Safety Results in Phase 3 Trial of Oral PPD Treatment

Reuters
·
Nov 18, 2025

Lipocine Inc: Topline Results Are on Track for Q2 of 2026

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Inc: per Drug Safety Monitoring Board (Dsmb) Meeting Evaluating One-Third of Planned Participants, Study to Continue as Planned

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Inc - No Dose Reductions or Drug-Related Saes Reported

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of Lpcn 1154 in Postpartum Depression (Ppd)

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 13, 2025

Lipocine (LPCN) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Nov 13, 2025

Lipocine (LPCN) Gets a Buy from Alliance Global Partners

TIPRANKS
·
Nov 08, 2025

Lipocine Inc. Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07, 2025

Lipocine Q3 EPS $(0.59) Misses $(0.55) Estimate, Sales $114.574K Miss $238.000K Estimate

Benzinga
·
Nov 06, 2025

Lipocine posts Q3 net loss of $3.2 million on $831,000 revenue

Reuters
·
Nov 06, 2025

BRIEF-Lipocine Q3 EPS USD -0.59

Reuters
·
Nov 06, 2025

Press Release: Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Dow Jones
·
Nov 06, 2025

Lipocine Presents Promising LPCN 2401 Data at ObesityWeek

TIPRANKS
·
Nov 04, 2025